Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Cepharanthine analogues, especially tetrandrine, show potential for treating COVID-19.

The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.

HIV medication ritonavir can increase the effects of nasal sprays like fluticasone, causing Cushing's syndrome.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

A blood pressure drug, diltiazem, may also help treat influenza.

Apremilast did not work for treating severe alopecia areata.

Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.

Acitretin treats severe skin conditions but requires careful monitoring due to serious side effects.

Cepharanthine shows promise as a COVID-19 treatment.

Skin disorders in HIV patients have shifted, with more sexually transmitted infections and ART-related conditions now common.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

PrEP implants are promising for HIV prevention if the number of implants needed is minimized.

Ritlecitinib can help about 14,000 people with severe hair loss.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.

Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.

TAK-279 effectively reduces psoriasis symptoms and is safe.